Seegene Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Seegene wird ein Gewinn- und Umsatzwachstum von 129.2% bzw. 13.1% pro Jahr prognostiziert, während der Gewinn pro Aktie um 129.3% pro Jahr wachsen soll.

Wichtige Informationen

129.2%

Wachstumsrate der Gewinne

129.3%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	53.2%
Wachstumsrate der Einnahmen	13.1%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	16 Apr 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

A Look At The Fair Value Of Seegene, Inc. (KOSDAQ:096530)

Mar 07

Is Seegene, Inc. (KOSDAQ:096530) Trading At A 32% Discount?

May 06

I Ran A Stock Scan For Earnings Growth And Seegene (KOSDAQ:096530) Passed With Ease

Mar 15

Declining Stock and Solid Fundamentals: Is The Market Wrong About Seegene, Inc. (KOSDAQ:096530)?

Dec 23

Can You Imagine How Elated Seegene's (KOSDAQ:096530) Shareholders Feel About Its 656% Share Price Gain?

Dec 08

I Ran A Stock Scan For Earnings Growth And Seegene (KOSDAQ:096530) Passed With Ease

Nov 24

Gewinn- und Umsatzwachstumsprognosen

KOSDAQ:A096530 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (KRW Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	460,250	48,700	N/A	N/A	2
12/31/2024	397,050	17,200	N/A	N/A	2
3/31/2024	367,272	-3,461	43,736	74,663	N/A
12/31/2023	367,375	669	63,053	94,932	N/A
9/30/2023	389,688	-2,578	60,269	96,806	N/A
6/30/2023	448,646	-8,971	38,577	80,689	N/A
3/31/2023	492,159	18,719	34,182	92,771	N/A
12/31/2022	853,561	182,139	246,557	319,009	N/A
9/30/2022	1,140,776	343,230	323,190	401,561	N/A
6/30/2022	1,295,241	447,057	496,227	579,900	N/A
3/31/2022	1,470,535	537,404	501,890	574,273	N/A
12/31/2021	1,370,833	536,559	267,913	334,024	N/A
9/30/2021	1,402,531	559,365	307,852	377,100	N/A
6/30/2021	1,424,097	618,128	153,723	331,480	N/A
3/31/2021	1,395,194	633,289	218,235	393,526	N/A
12/31/2020	1,125,216	502,281	207,900	383,157	N/A
9/30/2020	717,254	321,437	79,846	234,884	N/A
6/30/2020	421,777	175,809	73,584	103,313	N/A
3/31/2020	176,245	55,324	10,467	31,529	N/A
12/31/2019	121,953	26,672	22,354	27,141	N/A
9/30/2019	118,445	26,676	18,474	22,290	N/A
6/30/2019	110,402	23,176	18,418	21,008	N/A
3/31/2019	105,861	14,304	13,156	15,670	N/A
12/31/2018	102,265	10,098	10,045	14,010	N/A
9/30/2018	97,975	5,951	11,019	17,831	N/A
6/30/2018	94,684	4,972	7,785	9,870	N/A
3/31/2018	91,979	4,684	3,740	8,555	N/A
12/31/2017	88,920	3,693	N/A	10,115	N/A
9/30/2017	83,092	6,568	N/A	9,699	N/A
6/30/2017	80,817	4,644	N/A	19,233	N/A
3/31/2017	77,285	5,672	N/A	22,227	N/A
12/31/2016	73,694	7,123	N/A	16,557	N/A
9/30/2016	70,519	2,827	N/A	6,916	N/A
6/30/2016	67,973	6,367	N/A	705	N/A
3/31/2016	65,903	6,289	N/A	-607	N/A
12/31/2015	65,137	6,774	N/A	-3,122	N/A
9/30/2015	63,834	9,204	N/A	6,752	N/A
6/30/2015	63,538	8,620	N/A	9,213	N/A
3/31/2015	63,807	8,412	N/A	12,028	N/A
12/31/2014	64,411	9,141	N/A	6,777	N/A
9/30/2014	65,029	8,021	N/A	4,132	N/A
6/30/2014	65,141	8,067	N/A	1,292	N/A
3/31/2014	62,595	9,414	N/A	-5,939	N/A
12/31/2013	58,993	9,573	N/A	-2,893	N/A
9/30/2013	58,798	10,338	N/A	-3,491	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: A096530 wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.5%).

Ertrag vs. Markt: A096530 wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: A096530 wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: A096530Die Einnahmen des Unternehmens (11.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt KR (10.2% pro Jahr).

Hohe Wachstumseinnahmen: A096530Die Einnahmen des Unternehmens (11.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von A096530 in 3 Jahren voraussichtlich hoch sein wird

Seegene Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 8.8% to ₩25,000

Consensus EPS estimates fall from profit to ₩18.00 loss

Consensus revenue estimates fall by 21%

Price target decreased to ₩38,667

Consensus revenue estimates fall by 24%

Price target decreased to ₩71,500

Recent updates

Upcoming dividend of ₩200 per share

Now 20% overvalued

Upcoming dividend of ₩200 per share

Full year 2023 earnings: EPS and revenues exceed analyst expectations

A Look At The Fair Value Of Seegene, Inc. (KOSDAQ:096530)

New minor risk - Share price stability

Now 28% overvalued after recent price rise

Upcoming dividend of ₩200 per share at 3.5% yield

Price target decreased by 8.8% to ₩25,000

New minor risk - Share price stability

Upcoming dividend of ₩200 per share at 3.7% yield

Consensus EPS estimates fall from profit to ₩18.00 loss

New minor risk - Share price stability

Investor sentiment improves as stock rises 18%

Seegene Inc. Unveils Solutions to Popularize Molecular Diagnostics At 2023 AACC

Seegene, Inc. (KOSDAQ:A096530) announces an Equity Buyback for KRW 30,000 million worth of its shares.

Upcoming dividend of ₩200 per share at 3.7% yield

Upcoming dividend of ₩200 per share at 3.1% yield

Full year 2022 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 21%

Upcoming dividend of ₩400 per share

Investor sentiment deteriorated over the past week

Price target decreased to ₩38,667

Less than half of directors are independent

Seegene, Inc. (KOSDAQ:A096530) announces an Equity Buyback for KRW 50,000 million worth of its shares.

Upcoming dividend of ₩200 per share

Consensus revenue estimates fall by 24%

Now 20% undervalued

Investor sentiment improved over the past week

Seegene, Inc. to Pave Way for PCR Testing At Local Clinics with EU-Approved Multiplex Test and Fully Automated PCR Solution

Seegene Inc. Develops PCR Test to Detect Monkeypox Virus

Upcoming dividend of ₩400 per share

Now 24% undervalued after recent price drop

Price target decreased to ₩71,500

Seegene, Inc. Unveils World's First Commercialized '3 Ct' PCR Assay

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Now 21% undervalued after recent price drop

Seegene's Allplex™ RV Master Assay Receives Australian TGA Approval

Full year 2021 earnings: EPS and revenues miss analyst expectations

Seegene Inc. Unveils New Assay Optimized for On-Site Testing in 'Living with Covid-19' Era

Consensus revenue estimates increase by 13%

Consensus revenue estimates increase by 10%

Investor sentiment improved over the past week

Seegene Inc. to Launch New COVID-19 PCR Test with a Reduced Turnaround Time Optimized for Mass Testing

Seegene Inc. Announces Allplex Sars Cov-2 FluA/FluB/RSV Assay Approved Under Health Canada's Interim Order

Seegene Inc. Unveils Another Series of Diagnostic Test that Detects the Ever-Changing COVID-19 Variant Landscape

Seegene's High Multiplex Pcr Assay Capable of Detecting New Omicron Variant

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Seegene Inc. Unveils Fully Automated Molecular Testing System At the 2021 AACC

Price target decreased to ₩89,000

Consensus EPS estimates increase to ₩9,305

Seegene Introduces New SARS-CoV-2 Variants Detection Test That Can Screen Six Virus Variants Including the Delta and Delta Plus

Seegene Inc. Introduces its New Deployable Container Laboratory "Mobile Station", at the Medlab Middle East 2021

Investor sentiment improved over the past week

Price target decreased to ₩116,750

Seegene, Inc. Introduces an Exclusive Diagnostic System for Diagnosing Covid-19 Variants

Is Seegene, Inc. (KOSDAQ:096530) Trading At A 32% Discount?

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS ₩19,324 (vs ₩1,026 in FY 2019)

I Ran A Stock Scan For Earnings Growth And Seegene (KOSDAQ:096530) Passed With Ease

Seegene Announces Submission to U.S. FDA for Emergency Use Authorization of Its AllplexTM SARS-CoV-2/FluA/FluB/RSV Assay

Price target lowered to ₩291,800

Does Seegene (KOSDAQ:096530) Have A Healthy Balance Sheet?

Investor sentiment deteriorated over the past week

New 90-day low: ₩153,900

Seegene, Inc. to Report Fiscal Year 2020 Results on Feb 18, 2021